专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07323296B2 Method and index for diagnosing insulin resistance 失效
标题翻译：诊断胰岛素抵抗的方法和指标
公开(公告)号：US07323296B2
公开(公告)日：2008-01-29
申请号：US11240221
申请日：2005-09-30
申请人： Yuanhong Ma , Gerald M. Reaven , Yuanshu Xie , Xingyu Wang , Lynn E. Murry
发明人： Yuanhong Ma , Gerald M. Reaven , Yuanshu Xie , Xingyu Wang , Lynn E. Murry
IPC分类号： A01N1/02 , G01N33/48
CPC分类号： G01N33/6893 , G01N33/92 , G01N2800/042
摘要： The invention provides a method for the determination of insulin sensitivity, insulin resistance, and non-insulin dependent Diabetes mellitus based on oral glucose tolerance test data and lipid ratios from reference populations that define an insulin resistance index. The invention also provides methods for using the IR index to determine disease progression and to evaluate the efficacy of the therapeutic agents. The invention further provides an IR calculator for automating diagnosis, producing and storing patient medical records.
摘要翻译：本发明提供了一种基于定义胰岛素抵抗指数的参考群体的口服葡萄糖耐量测试数据和脂质比例来确定胰岛素敏感性，胰岛素抵抗和非胰岛素依赖性糖尿病的方法。本发明还提供使用IR指数来确定疾病进展并评估治疗剂的功效的方法。本发明还提供一种IR计算器，用于自动诊断，产生和存储患者医疗记录。

2. 发明申请

US20090191576A1 Method and index for diagnosing insulin resistance 审中-公开
标题翻译：诊断胰岛素抵抗的方法和指标
公开(公告)号：US20090191576A1
公开(公告)日：2009-07-30
申请号：US12011514
申请日：2008-01-28
申请人： Yuanhong Ma , Yuanshu Xie , Gerald Reaven , Xingyu Wang , Lynn Ellen Murry
发明人： Yuanhong Ma , Yuanshu Xie , Gerald Reaven , Xingyu Wang , Lynn Ellen Murry
IPC分类号： C12Q1/54 , C12Q1/60
CPC分类号： C12Q1/006 , G01N2333/62 , G01N2405/02 , G01N2800/042
摘要： The invention provides methods for the determination of insulin sensitivity, insulin resistance, and non-insulin dependent Diabetes mellitus based on oral glucose tolerance test data and lipid ratios from reference populations that define an insulin resistance index. The invention also provides methods for using the IR index to determine disease progression and to evaluate the efficacy of therapeutic agents. The invention further provides an IR calculator for automating diagnosis, producing and storing patient medical records.
摘要翻译：本发明提供了基于定义胰岛素抵抗指数的来自参考群体的口服葡萄糖耐量试验数据和脂质比率来确定胰岛素敏感性，胰岛素抵抗和非胰岛素依赖性糖尿病的方法。本发明还提供了使用IR指数来确定疾病进展并评价治疗剂的功效的方法。本发明还提供一种IR计算器，用于自动诊断，产生和存储患者医疗记录。

3. 发明申请

US20060073097A1 Method and index for diagnosing insulin resistance 失效
标题翻译：诊断胰岛素抵抗的方法和指标
公开(公告)号：US20060073097A1
公开(公告)日：2006-04-06
申请号：US11240221
申请日：2005-09-30
申请人： Yuanhong Ma , Yuanshu Xie , Gerald Reaven , Xingyu Wang , Lynn Murry
发明人： Yuanhong Ma , Yuanshu Xie , Gerald Reaven , Xingyu Wang , Lynn Murry
IPC分类号： A61K49/00 , C12Q1/54
CPC分类号： G01N33/6893 , G01N33/92 , G01N2800/042
摘要： The invention provides a method for the determination on of insulin sensitivity, insulin resistance, and non-insulin dependent Diabetes mellitus based on oral glucose tolerance test data and lipid ratios from reference populations that define an insulin resistance index he invention also provides m for using the IR index to determine disease progression and to evaluate the efficacy of the therapeutic agents. The invention further provides an IR calculator for automating diagnosis, producing and storing patient medical records.
摘要翻译：本发明提供了一种基于口服葡萄糖耐量测试数据和参考群体的脂质比例来确定胰岛素敏感性，胰岛素抵抗和非胰岛素依赖性糖尿病的方法，该方法定义了他本发明还提供的用于使用 IR指数以确定疾病进展并评估治疗剂的功效。本发明还提供一种IR计算器，用于自动诊断，产生和存储患者医疗记录。

4. 发明申请

US20070003946A1 Use of biomarkers in screening for insulin resistance 审中-公开
标题翻译：使用生物标志物筛查胰岛素抵抗
公开(公告)号：US20070003946A1
公开(公告)日：2007-01-04
申请号：US11297512
申请日：2005-12-08
申请人： Yuanhong Ma , Xingyu Wang , Lisheng Liu
发明人： Yuanhong Ma , Xingyu Wang , Lisheng Liu
IPC分类号： C12Q1/68 , C07H21/04
CPC分类号： C12Q1/6883 , C12Q2600/156 , C12Q2600/158
摘要： The invention relates to methods and biomarkers useful in screening subjects for insulin resistance and for monitoring insulin resistance over time or after medical intervention.
摘要翻译：本发明涉及用于筛选受试者胰岛素抵抗和用于随时间或医疗干预后监测胰岛素抵抗的方法和生物标志物。

5. 发明授权

US5658729A Method, reagent and kit for evaluating susceptibility to premature atherosclerosis 失效
标题翻译：用于评估早产动脉粥样硬化易感性的方法，试剂和试剂盒
公开(公告)号：US5658729A
公开(公告)日：1997-08-19
申请号：US320604
申请日：1994-10-11
申请人： Michael R. Hayden , Yuanhong Ma , Suzanne Lewis , Guoquing Liu
发明人： Michael R. Hayden , Yuanhong Ma , Suzanne Lewis , Guoquing Liu
IPC分类号： A61K38/46 , A61K48/00 , C12N9/20 , C12N15/55 , C12Q1/68 , C07H21/04 , C12P19/34
CPC分类号： C12Q1/6883 , C12N9/20 , C12Y301/01003 , A61K38/00 , A61K48/00 , C12N2799/022 , C12N2799/027 , C12Q1/683 , C12Q2600/156 , Y10S435/81
摘要： A single point mutation in the human lipoprotein lipase gene which results in an A.fwdarw.G nucleotide change at codon 291 (nucleotide 1127) of the lipoprotein lipase gene, and a substitution of serine for the normal asparagine in the lipoprotein lipase gene product is seen with increased frequency in patients with coronary artery disease, and is associated with an increased susceptibility to coronary artery disease, including in particular premature atherosclerosis. This is expressed as a diminished catalytic activity of lipoprotein lipase, lower HDL-cholesterol levels and higher triglyceride levels. Thus, susceptibility of a human individual to premature atherosclerosis and other forms of coronary artery disease can be evaluated byevaluating the sample of DNA for the presence of nucleotides encoding a serine residue as amino acid 291 of the lipoprotein lipase gene product. The presence of a serine residue is indicative of increased susceptibility in the patient. This method may be performed using a kit which contains a pair of primers selected to amplify a region of a human lipoprotein lipase gene spanning amino acid 291 of human lipoprotein lipase.
摘要翻译：人脂蛋白脂肪酶基因中的单点突变导致脂蛋白脂肪酶基因的291密码子（核苷酸1127）的A→G核苷酸变化，以及脂蛋白脂肪酶基因产物中正常天冬酰胺的丝氨酸取代冠状动脉疾病患者的频率增加，并且与冠状动脉疾病的易感性增加相关，特别是早产动脉粥样硬化。这表达为脂蛋白脂肪酶的催化活性降低，HDL-胆固醇水平降低，甘油三酯水平升高。因此，可以通过评估DNA样品中编码丝氨酸残基的核苷酸的存在作为脂蛋白脂肪酶基因产物的氨基酸291来评估人类对过早的动脉粥样硬化和其他形式的冠状动脉疾病的易感性。丝氨酸残基的存在表明患者易感性增加。该方法可以使用包含选择用于扩增跨越人类脂蛋白脂肪酶的氨基酸291的人类脂蛋白脂肪酶基因的区域的一对引物的试剂盒来进行。

6. 发明授权

US06784162B1 Gene therapy method for reducing risk of atherosclerosis 失效
标题翻译：降低动脉粥样硬化风险的基因治疗方法
公开(公告)号：US06784162B1
公开(公告)日：2004-08-31
申请号：US08817192
申请日：1997-07-10
申请人： Michael R. Hayden , Yuanhong Ma , Suzanne Lewis , Guoquing Liu
发明人： Michael R. Hayden , Yuanhong Ma , Suzanne Lewis , Guoquing Liu
IPC分类号： A61K4800
CPC分类号： C12Q1/6883 , A61K38/00 , A61K48/00 , C12N9/20 , C12N2799/022 , C12N2799/027 , C12Q1/683 , C12Q2600/156 , C12Y301/01003 , Y10S435/81
摘要： A single point mutation in the human lipoprotein lipase gene which results in an A→G nucleotide change at codon 291 (nucleotide 1127) of the lipoprotein lipase gene, and a substitution of serine for the normal asparagine in the lipoprotein lipase gene product is seen with increased frequency in patients with coronary artery disease, and is associated with an increased susceptibility to coronary artery disease, including in particular premature atherosclerosis. This is expressed as a diminished catalytic activity of lipoprotein lipase, lower HDL-cholesterol levels and higher triglyceride levels. Thus, susceptibility of a human individual to premature atherosclerosis can be evaluated by: (a) obtaining a sample of DNA from the individual; and (b) evaluating the sample of DNA for the presence of nucleotides encoding a serine residue as amino acid 291 of the lipoprotein lipase gene product. The presence of a serine residue is indicative of increased susceptibility in the patient. This method may be performed using a kit which contains a pair of primers selected to amplify a region of a human lipoprotein lipase gene spanning amino acid 291 of human lipoprotein lipase. Appropriate additional reagents may also be included in the kit such as polymerase enzymes, nucleoside stock solutions and the like. Patients found to be suffering from or likely to suffer from premature atherosclerosis and other forms of coronary artery disease as a result of a lipoprotein lipase deficiency can be treated using gene therapy. This may be accomplished using adenovirus-mediated or retrovirus-mediated gene therapy, and can be performed using either an in vivo or an ex vivo approach.
摘要翻译：人脂蛋白脂肪酶基因中的单点突变导致脂蛋白脂肪酶基因的291密码子（核苷酸1127）的A→G核苷酸变化，以及脂蛋白脂肪酶基因产物中丝氨酸取代正常的天冬酰胺。冠状动脉疾病患者的频率增加，并且与冠状动脉疾病的易感性增加相关，特别是早产动脉粥样硬化。这表达为脂蛋白脂肪酶的催化活性降低，HDL-胆固醇水平降低，甘油三酯水平升高。因此，人类对早产动脉粥样硬化的易感性可以通过以下方式来评估：（a）从个体获得DNA样品; 和（b）评估DNA样品中编码丝氨酸残基的核苷酸的存在，作为脂蛋白脂肪酶基因产物的氨基酸291。丝氨酸残基的存在表明患者易感性增加。该方法可以使用包含选择用于扩增跨越人类脂蛋白脂肪酶的氨基酸291的人类脂蛋白脂肪酶基因的区域的一对引物的试剂盒来进行。试剂盒中还可以包括合适的另外的试剂，例如聚合酶，核苷储备溶液等。发现由于脂蛋白脂肪酶缺乏而发现患有或可能患有过早动脉粥样硬化和其他形式的冠状动脉疾病的患者可以使用基因治疗来治疗。这可以使用腺病毒介导的或逆转录病毒介导的基因治疗来实现，并且可以使用体内或离体方法进行。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式